- Plot 17, Crested Towers, Floor 9, Hannington Rd, Kampala
- reap@finance.go.ug
- +256 414 347063
Uganda’s Fight Against Tuberculosis: Global Fund Support
key statistics on the impact of tuberculosis (TB) in Uganda, particularly regarding the support from the Global Fund:
Prevalence: Uganda reported approximately 98,000 new TB cases in 2021, with an incidence rate of 227 cases per 100,000 population.
Case Detection: The Global Fund has significantly contributed to the detection of over 70,000 TB cases annually, leading to a 75% treatment success rate in the country.
Multi-Drug Resistant TB (MDR-TB): Uganda has enrolled over 4,000 patients on MDR-TB treatment, receiving vital support and medications through Global Fund initiatives.
Community Engagement: More than 1 million people have been educated about TB symptoms and the importance of seeking treatment through community outreach programs, bolstered by Global Fund funding.
Integration with HIV Services: Approximately 40% of TB patients in Uganda are also living with HIV. The Global Fund has facilitated integrated services to co-treat these patients, enhancing overall health outcomes.
These statistics highlight the Global Fund’s significant impact on improving TB care and reducing its burden in Uganda.
Tuberculosis (TB) remains a significant public health challenge in Uganda, with the country ranking among the top 30 high-burden countries globally. In 2021, Uganda reported an estimated 98,000 new TB cases, which translates to an incidence rate of 227 cases per 100,000 population. With the continued support of the Global Fund, Uganda has made significant strides in TB prevention, diagnosis, and treatment, aiming to reduce the burden of this disease.
Global Fund Support
Since 2002, the Global Fund has played a pivotal role in Uganda’s TB response by committing over $250 million to strengthen the national TB program. This support has been vital in enhancing the quality of TB care, improving access to diagnostics and treatment, and implementing community-based initiatives that focus on prevention and awareness.
Key Achievements
Increased Case Detection: The Global Fund has supported efforts that led to the detection of over 70,000 TB cases annually, representing a 75% treatment success rate. Enhanced diagnostic methods, including GeneXpert technology, have played a crucial role in improving case identification.
Multi-Drug Resistant TB (MDR-TB): Uganda has made significant strides in addressing MDR-TB, with over 4,000 patients enrolled on treatment. The Global Fund has been instrumental in providing the necessary medications and support to ensure adherence and successful outcomes.
Community Engagement: Community health workers have been engaged to raise awareness and facilitate access to TB services. Through outreach programs, more than 1 million people have been educated about TB symptoms and the importance of seeking treatment.
Integrated Services: TB services are being integrated with HIV programs, recognizing the close link between the two diseases. Approximately 40% of TB patients are also living with HIV, and the Global Fund has facilitated the provision of co-treatment for these patients.
Ongoing Challenges
Despite significant progress, Uganda continues to face challenges in its TB response, including stigma, underreporting, and the need for increased funding for TB services. The Global Fund remains committed to addressing these barriers and improving health outcomes for all Ugandans.
Statistics at a Glance
Looking Forward
Uganda aims to eliminate TB as a public health threat by 2030, aligning with the WHO End TB Strategy. With ongoing support from the Global Fund, Uganda is working towards achieving this goal, focusing on increased case detection, treatment adherence, and reducing transmission rates in vulnerable populations.
The Funds Coordination Unit (FCU) was set up in the Ministry of Finance, Planning and Economic Development (MoFPED) as the Principal Recipient (PR) to handle day-to-day oversight duties as they relate to the implementation of the Global Fund Grants.